Tau phosphorylated at threonine 181 (p-tau181) has been established as a biomarker for Alzheimer’s disease when measured in CSF, but many obstacles prevent its routine use in clinical settings. Join us for a lively discussion around an innovative immunoassay to measure p-tau 181 in blood (plasma and serum), paving the way for new tools to help fight this devastating disease. The discussion will examine the role of ultrasensitivity in biomarker detection and the future of Simoa® in Alzheimer’s disease research.
For an introduction to the research, please review the recent study below. It will be discussed further during this webinar: Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
Kevin Hrusovsky, Founder of Powering Precision Health and Chairman and CEO of Quanterix
Henrik Zetterberg, M.D., Ph.D., Professor of Neurochemistry, University of Gothenburg, Sweden
Kaj Blennow, M.D., Ph.D., Professor of Neurochemistry, University of Gothenburg, Sweden
Quanterix is pleased to sponsor this webinar hosted by Powering Precision Health.